Key result
Resting tachycardia linked to ~16-fold higher 30-day mortality versus <80 bpm in hospitalized COVID-19 patients.
Why the study?
The study evaluated the association between higher resting heart rates and adverse events in patients with COVID-19.
Does an elevated resting heart rate predict all-cause mortality and ventilator use in hospitalized patients with COVID-19?
Cohort (n=136)
No
Does an elevated resting heart rate predict all-cause mortality and ventilator use in hospitalized patients with COVID-19?
Elevated average resting heart rate during the first 3 days of hospitalization is an independent predictor of 30-day all-cause mortality and ventilator use in severe COVID-19 patients.
BACKGROUND: We evaluated the association between higher resting heart rates (RHRs) and adverse events in COVID-19 patients. METHODS: One hundred and thirty-six patients with laboratory-confirmed COVID-19 were admitted. Outcomes of patients with different RHRs were compared. CONCLUSIONS: Elevated average RHRs during the first 3 days of hospitalisation were associated with adverse outcomes in COVID-19 patients. Average RHRs as tachycardia can independently predict all-cause mortality.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2021) conducted a cohort in COVID-19 (n=136). Elevated resting heart rate (≥100 bpm) vs. Resting heart rate <80 bpm was evaluated on 30-day all-cause mortality (HR 16.05, 95% CI 1.70-151.24, p=0.015). Elevated mean resting heart rate as tachycardia (≥100 bpm) independently predicted 30-day all-cause mortality (HR 16.05) compared to a resting heart rate <80 bpm in hospitalized patients with COVID-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: